Abstract
Inflammatory bowel diseases (IBD) are chronic relapsing and remitting disorders that have varying degrees of severity. However multiple studies have confirmed that a large proportion of patients on maintenance treatment lose response to anti-TNF therapy. This has led to increasing interest in the concept of ‘switching therapy out-of-class’ i.e. a nonanti- TNF antibody when patients either fail to respond (primary non-response, develop secondary non-response) or do not tolerate anti-TNF therapies. The most widely known and studied alternative class of antibodies therapies at present are the selective adhesion molecule inhibitors. Several antibodies exist which constitute selection adhesion molecule inhibitors, including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.
Keywords: anti-TNF, adalimumab, infliximab, Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, natalizumab, vedolizumab, alicaforsen,
Current Drug Delivery
Title:Anti-Adhesion Molecules: is Gut Specificity the Key for a Good Safety Profile?
Volume: 9 Issue: 4
Author(s): Patrick B Allen
Affiliation:
Keywords: anti-TNF, adalimumab, infliximab, Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, natalizumab, vedolizumab, alicaforsen,
Abstract: Inflammatory bowel diseases (IBD) are chronic relapsing and remitting disorders that have varying degrees of severity. However multiple studies have confirmed that a large proportion of patients on maintenance treatment lose response to anti-TNF therapy. This has led to increasing interest in the concept of ‘switching therapy out-of-class’ i.e. a nonanti- TNF antibody when patients either fail to respond (primary non-response, develop secondary non-response) or do not tolerate anti-TNF therapies. The most widely known and studied alternative class of antibodies therapies at present are the selective adhesion molecule inhibitors. Several antibodies exist which constitute selection adhesion molecule inhibitors, including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.
Export Options
About this article
Cite this article as:
B Allen Patrick, Anti-Adhesion Molecules: is Gut Specificity the Key for a Good Safety Profile?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323143
DOI https://dx.doi.org/10.2174/156720112801323143 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of Mechanical Aerosol Delivery Systems in an in vitro Model of Mechanically Ventilated Neonates
Recent Patents on Drug Delivery & Formulation Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Editorial (Thematic Issue: Macrophage Migration Inhibitory Factor (MIF) and Its Receptors – Interactions and Suitability as Biomarkers)
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy New Therapeutic Approaches by Using Microorganism-Derived Compounds
Current Medicinal Chemistry Multi-Functional Anti-HIV Agents Based on Amino Acid Sequences Present in Serpin C-Terminal Peptides
Anti-Infective Agents in Medicinal Chemistry Proteinase Inhibitors: A Promising Drug Class for Treating Leishmaniasis
Current Drug Targets Drug Hypersensitivity: Epidemiology and Risk Factors
Current Pharmaceutical Design Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Inflammation: A Multidimensional Insight on Natural Anti-Inflammatory Therapeutic Compounds
Current Medicinal Chemistry Small Intestinal Injury Caused by NSAIDs/Aspirin: Finding New from Old
Current Medicinal Chemistry Gene and process level modulation to overcome the bottlenecks of recombinant proteins expression in Pichia pastoris
Current Pharmaceutical Biotechnology Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases
Current Nanoscience One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Antibody Fusion Proteins: Applications in Brain Targeting
Current Medicinal Chemistry - Central Nervous System Agents <i>In vitro</i> and Molecular Docking Analysis of Quercetin as an Anti-inflammatory and Antioxidant
Current Pharmaceutical Design Research Progress and Future Development Potential of Oridonin in Pharmacological Activities
Current Molecular Pharmacology Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents S-Phase Kinase-Associated Protein-2 and Nuclear Factor-kappa Beta as Molecular Targets of Oral Burkitt’s Lymphoma Cell Induced by Quinolinone Derivate-Vesnarinone
Current Signal Transduction Therapy